About a third of all food produced is lost or wasted yearly. Besides painting a grim picture of world hunger, this is also responsible for harmful emissions. Tackling food waste, global biotech company Zoono (ASX: ZNO) has teamed up with England-based hygiene tech company OSY to distribute a tech that boosts the shelf-life of produce.
Read More
Melbourne-based therapeutic antibody development company Patrys (ASX: PAB) unveiled positive findings from preclinical studies using PAT-DX1 and PAT-DX3 in animal anti-neutrophil cytoplasmic antibody (ANCA) vasculitis models. Dr Kim O’Sullivan from Monash University presented the findings during the plenary session at the 21st International Vasculitis Workshop in Barcelona. He said, “Both PAT-DX1 and PAT-DX3 are able
Read More
Canadian biotech company Tryp Therapeutics (CSE: TRYP) is set to list on the ASX through a backdoor merger with genetic medicines developer Exopharm (ASX: EX1) in a $14.3 million acquisition agreement. Following this agreement, Exopharm will change its name to Tryp and re-list on the ASX. On completion of the Transaction (Completion), Exopharm will be
Read More
The conversations surrounding artificial intelligence (AI) and its scope to transform the pharma industry have been underway for a while now. In fact, reports suggest that the global health-related AI market is set to be worth $284bn by 2030. Pharmaceutical development company Algorae (ASX: 1AI) is one of the companies at the forefront of this
Read More
Despite global efforts, food waste remains a challenging problem to solve. Each year, 1.3 billion tons of food is wasted due to poor handling, costing the global economy $1.5 trillion. This waste contributes 6-8% of annual greenhouse gas emissions and, what’s more, if saved, it could have fed about 1.26 billion people. No doubt, food
Read More
Blood cancer patients undergoing chemotherapy could soon have a reduced dependence on blood transfusions thanks to a new clinical study announced, run in partnership between biotech company Syntara (ASX: SNT), the University of Newcastle and the Australasian Leukaemia and Lymphoma Group (ALLG). The Phase 2 clinical study has been backed by a $0.83m grant to
Read More